Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.66 |
| ▸ | DRD4 | P21917 | 6/20 | 0.64 |
| ▸ | DRD2 | P14416 | 5/20 | 0.64 |
| ▸ | DRD3 | P35462 | 5/20 | 0.64 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6851374 | 0.98 | HTR1B (0.63) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL2472084 | 0.94 | HTR1B (0.64) | HTR1BDRD4DRD2DRD3HTR1D | |
| Hydrochloric Acid SCHEMBL21595631 | 0.92 | HTR1B (0.62) | HTR1BDRD4DRD2DRD3HTR1D | |
| Hydrochloric Acid SCHEMBL5004335 | 0.85 | DRD4 (0.66) | HTR1BDRD4DRD2DRD3HTR1D | |
| Formic Acid SCHEMBL5072995 | 0.84 | DRD4 (0.55) | HTR1BDRD4DRD2DRD3HTR1D | |
| Dimethylamine SCHEMBL3444887 | 0.82 | DRD4 (0.56) | DRD4DRD2DRD3NPC1MEN1 | |
| SCHEMBL6255082 | 0.82 | HTR1B (0.68) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL14174988 | 0.82 | DRD2 (0.71) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL19957512 | 0.81 | HTR1B (0.61) | HTR1BDRD4DRD2DRD3HTR1D | |
| SCHEMBL9770319 | 0.80 | DRD4 (0.59) | DRD4DRD2DRD3NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017212423-A1 | CHEMCICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-14 | — | — | WO | disclosed |
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
| EP-0531253-B1 | N-substituted aminomethanediphosphonic acids | CIBA GEIGY AG (CH) | 1997-01-08 | — | — | EP | disclosed |
| US-5281748-A | N-substituted aminomethanediphosphonic acids | CIBA-GEIGY CORP. (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0531253-A1 | N-substituted aminomethanediphosphonic acids | CIBA-GEIGY AG (CH) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HTR1B 114/4885DRD4 1390/4885DRD2 668/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HTR1B 114/4885DRD4 1390/4885DRD2 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.